Following the introduction of PCV7 and later PCV13 in Madrid, Spain, there was a 70% reduction in the incidence of invasive pneumococcal disease in children less than 15 years of age. There was also a pronounced decline in the percentages of penicillin- and cefotaxime-resistant strains of the pneumococcus bacteria. After PCV13 was introduced in 2010, cefotaxime resistance among meningitis patients completely disappeared and both cefotaxime and penicillin resistance among non-meningitis cases declined to very low levels (<3%).
Full Citation:
Picazo JJ, Ruiz-Contreras J, Casado-Flores J et al.. 2019. Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: the HERACLES clinical surveillance study. Vaccine. 37(16).
Title of Article: Impact of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: the HERACLES clinical surveillance study
Author(s): Picazo JJ, Ruiz-Contreras J, Casado-Flores J et al.
Publication Year: 2019
Publication Name: Vaccine
Publication Volume: 37(16)
Publication Source URL: https://www.ncbi.nlm.nih.gov/pubmed/30902478
DOI (Digital Object Identifier): 10.1016/j.vaccine.2019.03.015
Topics: Antibiotic Resistance | Global Issues
Disease Vaccines: Pneumococcal disease/PCV/PPSV
Countries: Spain
WHO Regions: Europe